Resveratrol supplementation significantly decreased serum levels of CRP (MD -0.63; 95% CI -1.13 to -0.12; p=0.01) and TNF-α, but not IL-6, in patients with cardiovascular disease.
Meta-Analysis
Do resveratrol supplements reduce inflammatory biomarkers (TNF-α, IL-6, and CRP) in patients with cardiovascular disease?
Resveratrol supplementation significantly reduces inflammatory biomarkers CRP and TNF-α, but not IL-6, in patients with cardiovascular disease.
Effect estimate: MD -0.63 (95% CI -1.13, -0.12)
p-value: p=0.01
BACKGROUND: Chronic inflammation is one of the most important factors involved in the development and progression of cardiovascular disease (CVDs). Accumulating evidence has described the effect of resveratrol, a natural polyphenolic compound, on biomarkers of inflammation among patients with CVDs; however, findings are controversial. Here we performed a systematic review and meta-analysis of randomized controlled trials to evaluate the effect of resveratrol supplements on TNF-α, IL-6, and CRP levels in CVDs patients. METHODS: Online research was conducted in the following database: MEDLINE, EMBASE, Cochrane Library, Web of Science databases, and Scopus. This systematic review and meta-analysis were conducted to investigate the effects of resveratrol supplements on inflammatory biomarkers among patients with CVDs. The meta-analysis was performed using Comprehensive Meta-Analysis (CMA) V3 software. RESULTS: Six RCTs met the inclusion criteria and were selected for the current meta-analysis. Our results demonstrated that resveratrol significantly decreases serum levels of CRP (MD = -0.63, 95 % CI: -0.1.13, -0.12; p = 0.01), and TNF-α (MD = -0.55, 95 % CI: -1.04, -0.06; p = 0.02), however, resveratrol had not significant effect on serum concentration of IL-6 (MD = -0.12, 95 % CI: -0.52, 0.27; p = 0.53), in patients with CVDs. CONCLUSION: Our results suggest that resveratrol can be used as a potential treatment in patients with CVD by reducing inflammatory conditions.
Teimouri et al. (Tue,) conducted a meta-analysis in Cardiovascular disease. Resveratrol supplements was evaluated on Serum levels of CRP (MD -0.63, 95% CI -1.13, -0.12, p=0.01). Resveratrol supplementation significantly decreased serum levels of CRP (MD -0.63; 95% CI -1.13 to -0.12; p=0.01) and TNF-α, but not IL-6, in patients with cardiovascular disease.